Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Net Income (2022 - 2026)

Sagimet Biosciences' Net Income history spans 5 years, with the latest figure at -$10.6 million for Q1 2026.

  • Quarterly Net Income rose 41.41% to -$10.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$43.5 million through Mar 2026, up 23.82% year-over-year, with the annual reading at -$51.0 million for FY2025, 12.01% down from the prior year.
  • Net Income came in at -$10.6 million for Q1 2026, down from -$9.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$6.4 million in Q3 2023 to a low of -$18.2 million in Q1 2025.
  • The 5-year median for Net Income is -$8.1 million (2023), against an average of -$9.8 million.
  • Year-over-year, Net Income tumbled 174.19% in 2025 and then surged 41.41% in 2026.
  • Sagimet Biosciences' Net Income stood at -$7.2 million in 2022, then fell by 13.3% to -$8.2 million in 2023, then tumbled by 98.74% to -$16.2 million in 2024, then surged by 40.94% to -$9.6 million in 2025, then fell by 11.31% to -$10.6 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Net Income are -$10.6 million (Q1 2026), -$9.6 million (Q4 2025), and -$12.9 million (Q3 2025).